Carmignac Gestion’s ProQR Therapeutics PRQR Stock Holding History

Carmignac Gestion’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-34,377	Closed	-$477K	–	131
2019 Q1	$477K	Buy	+34,377	New	+$513K	0.01%	93

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

Carmignac Gestion's PRQR Position: Q2 2019 in Review

Carmignac Gestion sold out of ProQR Therapeutics (PRQR) in Q2 2019, closing a stake of 34,377 shares — an estimated $477K sold.

Carmignac Gestion first reported a position in PRQR in Q1 2019 and held it in 1 quarter. The position peaked at $477K in Q1 2019. 55 funds tracked by Wall St. Rank hold PRQR as of Q2 2019.

Carmignac Gestion reported no remaining ProQR Therapeutics position as of Q2 2019 after selling out during the quarter.
Carmignac Gestion sold 34,377 ProQR Therapeutics shares in Q2 2019, an estimated $477K.
Carmignac Gestion first reported a position in ProQR Therapeutics in Q1 2019 and held it in 1 quarter.
Carmignac Gestion's ProQR Therapeutics position peaked at $477K in Q1 2019.
55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2019.

Based on Carmignac Gestion's 13F filing for Q2 2019, filed 13 Aug 2019.